Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study

Hiba Fatayer; Rachel L. O’Connell; Finian Bannon; Charlotte E. Coles; Ellen Copson; Ramsey I. Cutress; Rajiv V. Dave; Matthew D. Gardiner; Margaret Grayson; Christopher Holcombe; Sheeba Irshad; Gareth W. Irwin; Ciara O’Brien; Carlo Palmieri; Abeer M. Shaaban; Nisha Sharma; Jagdeep K. Singh; Ian Whitehead; Shelley Potter; Stuart A. McIntosh; H. Curry; E. Iddles; M. Mahmood; Y. Masannat; J. Schneider; L. Simpson; M. Sidapra; L. Baker; H. Capitelli-McMahon; M. Hughes; A. Isaac; B. Skelly; C. Sirianni; N. Hirst; R. Linforth; A. Botes; T. Robinson; T. Schrire; J. Alfred; H. Lennon; D. Dumitru; E. Kleidi; F. Hoar; E. MacInnes; K. Sharma; T. Alaguthurai; N. Chand; C. A. Farulla; A. Hayward; B. Pearce; NeST Study Research Collaborative

doi:10.1093/bjs/znac131

Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study

Hiba Fatayer, Rachel L. O’Connell, Finian Bannon, Charlotte E. Coles, Ellen Copson, Ramsey I. Cutress, Rajiv V. Dave, Matthew D. Gardiner, Margaret Grayson, Christopher Holcombe, Sheeba Irshad, Gareth W. Irwin, Ciara O’Brien, Carlo Palmieri, Abeer M. Shaaban, Nisha Sharma, Jagdeep K. Singh, Ian Whitehead, Shelley Potter, Stuart A. McIntosh^*H. Curry, E. Iddles, M. Mahmood, Y. Masannat, J. Schneider, L. Simpson, M. Sidapra, L. Baker, H. Capitelli-McMahon, M. Hughes, A. Isaac, B. Skelly, C. Sirianni, N. Hirst, R. Linforth, A. Botes, T. Robinson, T. Schrire, J. Alfred, H. Lennon, D. Dumitru, E. Kleidi, F. Hoar, E. MacInnes, K. Sharma, T. Alaguthurai, N. Chand, C. A. Farulla, A. Hayward, B. Pearce, NeST Study Research Collaborative

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.

Original language	English
Pages (from-to)	800-803
Number of pages	4
Journal	British Journal of Surgery
Volume	109
Issue number	9
Early online date	11 May 2022
DOIs	https://doi.org/10.1093/bjs/znac131
Publication status	Published - 1 Sept 2022
Externally published	Yes

Bibliographical note

Funding Information:
This work was funded by a grant from the Association of Breast Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/bjs/znac131Licence: CC BY

Fatayer_BJS_Current_Practice_and_VOR
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), whichpermits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited
Final published version, 577 KBLicence: CC BY

Cite this

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., Irshad, S., Irwin, G. W., O’Brien, C., Palmieri, C., Shaaban, A. M., Sharma, N., Singh, J. K., Whitehead, I., Potter, S., ... NeST Study Research Collaborative (2022). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. British Journal of Surgery, 109(9), 800-803. https://doi.org/10.1093/bjs/znac131

Fatayer, H, O’Connell, RL, Bannon, F, Coles, CE, Copson, E, Cutress, RI, Dave, RV, Gardiner, MD, Grayson, M, Holcombe, C, Irshad, S, Irwin, GW, O’Brien, C, Palmieri, C, Shaaban, AM, Sharma, N, Singh, JK, Whitehead, I, Potter, S, McIntosh, SA, Curry, H, Iddles, E, Mahmood, M, Masannat, Y, Schneider, J, Simpson, L, Sidapra, M, Baker, L, Capitelli-McMahon, H, Hughes, M, Isaac, A, Skelly, B, Sirianni, C, Hirst, N, Linforth, R, Botes, A, Robinson, T, Schrire, T, Alfred, J, Lennon, H, Dumitru, D, Kleidi, E, Hoar, F, MacInnes, E, Sharma, K, Alaguthurai, T, Chand, N, Farulla, CA, Hayward, A, Pearce, B & NeST Study Research Collaborative 2022, 'Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study', British Journal of Surgery, vol. 109, no. 9, pp. 800-803. https://doi.org/10.1093/bjs/znac131

@article{e501ed3d5df54dcc9012c176f2d4711a,

title = "Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study",

abstract = "Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.",

author = "Hiba Fatayer and O{\textquoteright}Connell, {Rachel L.} and Finian Bannon and Coles, {Charlotte E.} and Ellen Copson and Cutress, {Ramsey I.} and Dave, {Rajiv V.} and Gardiner, {Matthew D.} and Margaret Grayson and Christopher Holcombe and Sheeba Irshad and Irwin, {Gareth W.} and Ciara O{\textquoteright}Brien and Carlo Palmieri and Shaaban, {Abeer M.} and Nisha Sharma and Singh, {Jagdeep K.} and Ian Whitehead and Shelley Potter and McIntosh, {Stuart A.} and H. Curry and E. Iddles and M. Mahmood and Y. Masannat and J. Schneider and L. Simpson and M. Sidapra and L. Baker and H. Capitelli-McMahon and M. Hughes and A. Isaac and B. Skelly and C. Sirianni and N. Hirst and R. Linforth and A. Botes and T. Robinson and T. Schrire and J. Alfred and H. Lennon and D. Dumitru and E. Kleidi and F. Hoar and E. MacInnes and K. Sharma and T. Alaguthurai and N. Chand and Farulla, {C. A.} and A. Hayward and B. Pearce and {NeST Study Research Collaborative}",

note = "Funding Information: This work was funded by a grant from the Association of Breast Surgery ",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/bjs/znac131",

language = "English",

volume = "109",

pages = "800--803",

journal = "British Journal of Surgery",

issn = "0007-1323",

publisher = "Oxford University Press (OUP)",

number = "9",

}

TY - JOUR

T1 - Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer

T2 - UK NeST study

AU - Fatayer, Hiba

AU - O’Connell, Rachel L.

AU - Bannon, Finian

AU - Coles, Charlotte E.

AU - Copson, Ellen

AU - Cutress, Ramsey I.

AU - Dave, Rajiv V.

AU - Gardiner, Matthew D.

AU - Grayson, Margaret

AU - Holcombe, Christopher

AU - Irshad, Sheeba

AU - Irwin, Gareth W.

AU - O’Brien, Ciara

AU - Palmieri, Carlo

AU - Shaaban, Abeer M.

AU - Sharma, Nisha

AU - Singh, Jagdeep K.

AU - Whitehead, Ian

AU - Potter, Shelley

AU - McIntosh, Stuart A.

AU - Curry, H.

AU - Iddles, E.

AU - Mahmood, M.

AU - Masannat, Y.

AU - Schneider, J.

AU - Simpson, L.

AU - Sidapra, M.

AU - Baker, L.

AU - Capitelli-McMahon, H.

AU - Hughes, M.

AU - Isaac, A.

AU - Skelly, B.

AU - Sirianni, C.

AU - Hirst, N.

AU - Linforth, R.

AU - Botes, A.

AU - Robinson, T.

AU - Schrire, T.

AU - Alfred, J.

AU - Lennon, H.

AU - Dumitru, D.

AU - Kleidi, E.

AU - Hoar, F.

AU - MacInnes, E.

AU - Sharma, K.

AU - Alaguthurai, T.

AU - Chand, N.

AU - Farulla, C. A.

AU - Hayward, A.

AU - Pearce, B.

AU - NeST Study Research Collaborative

N1 - Funding Information: This work was funded by a grant from the Association of Breast Surgery

PY - 2022/9/1

Y1 - 2022/9/1

N2 - Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.

AB - Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.

UR - http://www.scopus.com/inward/record.url?scp=85136908786&partnerID=8YFLogxK

U2 - 10.1093/bjs/znac131

DO - 10.1093/bjs/znac131

M3 - Article

C2 - 35543289

AN - SCOPUS:85136908786

SN - 0007-1323

VL - 109

SP - 800

EP - 803

JO - British Journal of Surgery

JF - British Journal of Surgery

IS - 9

ER -

Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this